No Data
No Data
Press Release: Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $4
Wedbush Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $8
Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects
Guang Bin Li :

Thank you for your Share.